Odyssey Therapeutics, Inc. Finite-Lived Intangible Assets, Accumulated Amortization
Odyssey Therapeutics, Inc. (ODTX) had Finite-Lived Intangible Assets, Accumulated Amortization of $1.64 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Assets, Accumulated Amortization $1.64M.
- 2026-03-31: Finite-Lived Intangible Assets, Accumulated Amortization $1.56M.
| Period end | Finite-Lived Intangible Assets, Accumulated Amortization |
|---|---|
| 2026-06-30 | $1.64M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.56M 10-Q · filed 2026-06-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |